NCT06137755

Safety and Immunogenicity of CVI-VZV-001 for Prevention of Herpes Zoster in Healthy Adults Age 50 Years and Above

A Multicenter, Active-controlled, Open-label Phase I Study to Assess Safety and Tolerability and to Explore Immunogenicity of CVI-VZV-001 Vaccine in Healthy Adults Aged 50 to 64 Years

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (estimated)
• Sponsor: CHA Vaccine Institute Co., Ltd. · Industry
• Sex: All
• Age: 50 Years – 64 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the safety and immunogenicity of the investigational medicinal product, CVI-VZV-001.

Detailed description

A Multicenter, Active-controlled, Open-label Phase I Study to Assess Safety and Tolerability and to Explore Immunogenicity of CVI-VZV-001 Vaccine in Healthy Adults Aged 50 to 64 Years

Conditions

• Vaccine-Preventable Diseases
• Herpes Zoster

Interventions

Type	Name	Description
BIOLOGICAL	CVI-VZV-001	Investigational Product
BIOLOGICAL	Shingrix	Investigational Product

Timeline

• Start date: 2023-03-15
• Primary completion: 2025-03-21
• Completion: 2025-03-21
• First posted: 2023-11-18
• Last updated: 2024-11-19

Locations

2 sites across 1 country: South Korea